Biomedical company ViaCyte raised $80m to develop its stem cell-derived therapies aimed at treating diabetes. The funding was led by Bain Capital Life Sciences and backed by TPG, RA Capital Management, existing investor Sanderling Ventures and private individuals. The firm combined technologies including stem cell biology, materials science and genetic editing in the development of therapies it said would supply insulin from insulin-creating beta cells. It was aimed at people suffering from type 2 diabetes who lacked their own beta cells. It would also be used by some type 1 patients.
Biomedical company ViaCyte raised $80m to develop its stem cell-derived therapies aimed at treating diabetes. The funding was led by Bain Capital Life Sciences and backed by TPG, RA Capital Management, existing investor Sanderling Ventures and private individuals. The firm combined technologies including stem cell biology, materials science and genetic editing in the development of therapies it said would supply insulin from insulin-creating beta cells. It was aimed at people suffering from type 1 diabetes who lacked their own beta cells. It would also be used by some type 2 patients.